Document is current
Any future updates will be listed below
-
Authors
Stewart, James
Krastev, Dragomir B. https://orcid.org/0000-0003-4298-7272
Brough, Rachel
Zatreanu, Diana
Song, Feifei
Baxter, Joseph S.
Sridhar, Sandhya
Frankum, Jessica
Konde, Asha
Yang, William https://orcid.org/0000-0002-6398-4508
Haider, Syed https://orcid.org/0000-0001-6685-5480
Alexander, John
Betteridge, Kai
Gulati, Aditi
Attygalle, Ayoma D.
Vroobel, Katherine
Natrajan, Rachael https://orcid.org/0000-0002-9987-2946
Khalique, Saira
Roumeliotis, Theodoros I. https://orcid.org/0000-0002-3354-5643
Choudhary, Jyoti S. https://orcid.org/0000-0003-0881-5477
Yeung, Jason https://orcid.org/0000-0003-2415-4824
Wicks, Andrew J. https://orcid.org/0000-0002-9307-3262
Marlow, Rebecca
Banerjee, Susana
Pettitt, Stephen J. https://orcid.org/0000-0003-3313-3857
Tutt, Andrew N. J. https://orcid.org/0000-0001-8715-2901
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
-
Funding
Funding for this research was provided by:
Cancer Research UK (DRCRPG-Nov21\100001)
- License Information
-
More Information
Article History
Received: 17 June 2024
Revised: 4 December 2024
Accepted: 12 December 2024
First Online: 12 February 2025
Competing interests
: CJL makes the following disclosures: receives and/or has received research funding from: AstraZeneca, Merck KGaA, Artios, Neophore. Received consultancy, SAB membership or honoraria payments from: FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures, Blacksmith Medicines, FoRx Therapeutics, Ariceum. Has stock in: Tango, Ovibio, Hysplex, Tesselate. CJL is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR “Rewards to Inventors” scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid into CJL’s personal account and research accounts at the Institute of Cancer Research. SB makes the following disclosure: receives and/or has received research funding from: AstraZeneca. Received consultancy, SAB membership or honoraria payments from Abbvie, Astrazeneca, Biontech, Eisai, Gilead, GlaxoSmithKline, Grey Wolf Therapeutics, Immunogen, Incyte, ITM Oncologics, Merck Sharpe Dohme, Mersana, Myriad, Oncxerna, Pharmaand, Seagen, Takeda. Verastem, Zymeworks.
